Nathon D. Wood, PHD,LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 8530 S. 500 W., Paradise, UT 84328 Phone: 435-789-3865 Fax: 435-789-3895 |
Dr. Donald Lee Hebert, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 8530 South 500 West, Paradise, UT 84328 Phone: 435-789-3865 |
News Archive
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Oncura, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Oncura is a unit of GE Healthcare. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Oncura, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada.
Earlier, scientists of the Diagnostics and Telemedicine Center already reported that they had collected the first database of CT studies of patients with laboratory-confirmed infection. It had about 50 CT scans of 20 patients.
The George Washington University School of Public Health and Health Services (GW) today released a report representing consensus findings from a cross-section of stakeholders that could help transform the process used to evaluate interventions to treat obesity, a public health crisis that now affects one in three adults. The report, "Obesity Drug Outcome Measures," results from a stakeholder dialogue group convened by GW that, over a period of nine months, explored why development and approval of obesity drugs have proven so difficult.
Researchers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment - to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination.
› Verified 4 days ago